News
After Decades Without Progress in Glioblastoma, Diakonos Stirs Up Interest in Dendritic Cell Vaccine
The firm is launching a Phase II trial of its dendritic cell vaccine following promising preliminary efficacy and favorable safety results in Phase I.
The FDA granted orphan drug designation to a CAR T-cell therapy for recurrent glioblastoma and high-grade astrocytomas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback